EU consults on Biotech Act II, protein firms seek clearer rules

Europe’s new biotech consultation has quickly become a test of policy clarity for fermentation-based protein companies: either Biotech Act II gives them a predictable route from lab work to factory buildout, or vague rules keep approvals slow and investors cautious. The European Commission’s call for evidence stays open until 10 June 2026, and the formal proposal is expected in the fourth quarter, putting the next few months at the center of a fight over how fast Europe can scale bio-based food technologies.

The Commission says Biotech Act II will follow the health-focused Biotech Act I and concentrate on industrial biotechnology and biomanufacturing. Its own materials frame the goal as creating an enabling environment, including measures to generate demand in lead markets and improve predictability for investors. The wider proposal also aims to turn Europe into a biotech powerhouse, expand access to funding, especially for start-ups and SMEs, simplify the regulatory environment and add biosecurity safeguards. That ambition lands against a familiar European problem: fragmented governance and weak coordination across Member States, which the Commission says has reduced the EU’s ability to deploy industrial facilities at scale.

For protein companies, that bottleneck is not abstract. Fermentation-derived ingredients, cultivated biomass and precision fermentation all depend on specialized facilities, authorizations and capital-intensive scale-up. If the regulatory path is murky, projects stall before they reach commercial volumes. If it is clear, companies can move faster on animal-free dairy, egg alternatives, fermented ingredients and other next-generation proteins that need industrial biomanufacturing rather than small-batch pilots.

That is why GFI Europe has pressed the Commission to treat the act as a critical opportunity to set a clear policy framework for food biotechnology. The group wants explicit support for fermentation-derived foods, precision fermentation and food biotechnology regulatory sandboxes. In a 2025 policy submission, it pointed to McKinsey analysis projecting the global advanced biotechnology market beyond pharmaceuticals could rise from $200 billion to $300 billion today to $700 billion to $1.1 trillion by 2040, with food biotechnology accounting for $130 billion to $395 billion of that total.

The EU’s own Bioeconomy Strategy, published in late 2025, adds another layer to the debate. It says the Commission will address regulatory obstacles in the upcoming Biotech Acts and create a European Bioeconomy Regulators and Innovators’ Forum to share risk-assessment best practices, monitor progress and bring firms into early discussions on novel bio-based solutions. Together, those moves show Brussels trying to decide whether Europe will build the rules, factories and investment climate needed to compete with the US and Asia, or leave fermentation-based proteins waiting for the next approval cycle.